Current Headlines

  1. AbTherx, Single Cell Technology, And Vaccinex Announce Collaboration To Tackle Challenging Antibody Drug Targets 5/13/2025

    AbTherx, Inc., a biotechnology company with innovative transgenic technologies that simplify and accelerate antibody discovery, today announced a collaboration with Single Cell Technology and Vaccinex. AbTherx and Single Cell Technology will incorporate Vaccinex's ActivMAb Technology into their respective workflows for complex drug targets.

  2. Comend And Odylia Partner To Advance Rare Disease Drug Development With Innovative Patient-Driven Platform 5/13/2025

    Comend, a software company building solutions for Patient Advocacy Groups (PAGs), and Odylia Therapeutics, a nonprofit drug development organization dedicated to advancing treatments for rare diseases, are excited to announce a strategic partnership aimed at transforming the rare disease research ecosystem.

  3. CytoTronics Expands Pixel Capability With Multi-Modal Cardiac Application For Early Screening Of Drug Candidates In Cardiovascular Research 5/13/2025

    CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, launched their novel Cardiac application today—the next key offering in its Pixel application portfolio.

  4. AI Tool Predicts Potential Drug Targets By Analyzing Cell Images 5/13/2025

    A new AI model developed by researchers at the Eric and Wendy Schmidt Center at the Broad Institute and ETH Zurich’s Department of Health Science and Technology can identify genes that have been altered, such as ones that might be causing a disease, in a cell just by analyzing an image of the cell’s chromatin — the dense package of chromosomes inside the cell’s nucleus.

  5. Thermosome Receives U.S. Orphan Drug Designation For Lead Compound THE001, Expands Patent Estate 5/12/2025

    Thermosome, a drug development company focused on targeted tumor therapies, today announced that its lead compound, THE001, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of soft tissue sarcomas (STS).

  6. NanoTemper Announces Prometheus Panta C: Powering Biopharma Breakthroughs From Preclinical To Commercial Manufacturing 5/12/2025

    NanoTemper Technologies today introduces Prometheus Panta C, a system built to power biopharma breakthroughs by delivering high-quality protein stability and aggregation data.

  7. Lantern Pharma Secures FDA Clearance For Planned Phase 1b/2 Trial Of LP-184 In Biomarker-Defined, Treatment-Resistant NSCLC Patients With High Unmet Clinical Need 5/12/2025

    Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR, today announced that the U.S. Food and Drug Administration (FDA) has cleared the amendment to its Investigational New Drug (IND) application to initiate a Phase 1b/2 clinical trial of LP-184 in a genomically defined patient population of non-small cell lung cancer (NSCLC) where there is a need to improve patient outcomes.

  8. Cell Death Discovery Could Lead To Next-Gen Drugs For Neurodegenerative Conditions 5/12/2025

    Researchers have discovered how to block cells dying, in a finding that could lead to new treatments for neurodegenerative conditions like Parkinson’s and Alzheimer’s.

  9. Intrepid Labs Launches To Transform Drug Formulation With AI And Autonomous Labs 5/12/2025

    Intrepid Labs, a biotechnology company transforming drug formulation development through the use of artificial intelligence (AI) and robotics, emerged from stealth today to accelerate therapeutics development through effective formulations that improve clinical performance.

  10. FDA Accepts Filing Application For Oral Semaglutide 25 mg, Which If Approved, Would Be The First Oral GLP-1 Treatment For Obesity 5/8/2025

    Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy® (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major adverse cardiovascular events (MACE) in adults with overweight or obesity and established cardiovascular disease.